• Press Release

Enzyme Dnmt1 in Developmental Myelination Process Could Lead to Better Understanding of Neurological Disorders

  • New York, NY
  • (April 14, 2016)

The removal of the enzyme Dnmt1 during oligodendrocyte progenitor cell (OPC) differentiation in the central nervous system resulted in inefficient myelin formation and neurological deterioration, including loss of control of bodily movements, in mice, according to a study conducted at the Icahn School of Medicine at Mount Sinai and published today in the medical journal Cell Reports.  The results could lead to a new understanding of multiple sclerosis and other myelin disorders in humans.

Oligodendrocytes (OLs) are cells with the ability to form a specialized membrane that is called “myelin.” Myelin is the insulating sheathing around the axons of nerve cells, which provides energetic support and allows for faster electrical impulse conduction.  OLs are derived from progenitors called OPCs, which are stem-like cells with the ability to divide and generate OLs through a complex process of gene regulation.  

This study shows that the development of OPCs into myelin-forming cells requires DNA methylation, which is a process consisting of the addition of chemical groups to the DNA carried out by enzymes called methyl transferases (DNMTs). When these groups are added, genes cannot be expressed and therefore are “silenced.”  The authors identify the many genes needed to be “silenced” in OPCs in order to allow for proper formation of myelin during development.

Researchers showed that the removal of Dnmt1 in oligodendrocyte lineage not only limited cell growth, but also led to cellular stress as well as severe and clinically symptomatic hypomelination – a reduced amount of myelin in nervous tissue.  The mice experienced significant neurological symptoms, such as tremors and a loss of control of body movement, and eventually death.

“Our group has previously observed altered DNA methylation in the brain of patients with multiple sclerosis, the most devastating adult demyelinating disorder, but its role in myelin formation and the identity of the genes silenced by DNMT’s in OPCs were not known,” says lead investigator Patrizia Casaccia, MD, PhD, Professor of Neuroscience, Genetics and Genomics, and Neurology, and Chief of the Center of Excellence for Myelin Repair at the Friedman Brain Institute at the Icahn School of Medicine.  “A better understanding of why DNA methylation is important for myelin formation and what genes need to be shut off during the formation of OLs from OPCs has important implications not only for development, but also for myelin repair.”

The research could lead to the development of treatment for disorders where the myelin sheath is damaged and could also help in understanding how OPCs transform into brain cancer cells.

Further study is needed to understand the causes underlying aberrant DNA methylation in the brains of multiple sclerosis patients and in preclinical models. Translational applications will include the identification of factors that could bypass impaired DNA methylation.

University of Cambridge, Universitӓt Erlangen-Nürnberg, Oregon Health and Science University, Sorbonne Université, University of California Los Angeles and Virginia Commonwealth University contributed to this research.

The National Institutes of Health (Award# R37NS042925) and the UK Multiple Sclerosis Society provided funding.  This research does not represent the official views of the NIH.


About the Mount Sinai Health System

The Mount Sinai Health System is New York City's largest integrated delivery system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai's vision is to produce the safest care, the highest quality, the highest satisfaction, the best access and the best value of any health system in the nation. The Health System includes approximately 7,480 primary and specialty care physicians; 11 joint-venture ambulatory surgery centers; more than 410 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. The Icahn School of Medicine is one of three medical schools that have earned distinction by multiple indicators: ranked in the top 20 by U.S. News & World Report's "Best Medical Schools", aligned with a U.S. News & World Report's "Honor Roll" Hospital, No. 12 in the nation for National Institutes of Health funding, and among the top 10 most innovative research institutions as ranked by the journal Nature in its Nature Innovation Index. This reflects a special level of excellence in education, clinical practice, and research. The Mount Sinai Hospital is ranked No. 18 on U.S. News & World Report's "Honor Roll" of top U.S. hospitals; it is one of the nation's top 20 hospitals in Cardiology/Heart Surgery, Gastroenterology/GI Surgery, Geriatrics, Nephrology, and Neurology/Neurosurgery, and in the top 50 in six other specialties in the 2018-2019 "Best Hospitals" issue. Mount Sinai's Kravis Children's Hospital also is ranked nationally in five out of ten pediatric specialties by U.S. News & World Report. The New York Eye and Ear Infirmary of Mount Sinai is ranked 11th nationally for Ophthalmology and 44th for Ear, Nose, and Throat. Mount Sinai Beth Israel, Mount Sinai St. Luke's, Mount Sinai West, and South Nassau Communities Hospital are ranked regionally.

For more information, visit https://www.mountsinai.org or find Mount Sinai on FacebookTwitter and YouTube.